A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.

Mario Cottone, Mario Cottone, Sara Renna, Ambrogio Orlando, Ambrogio Orlando, Sara Renna

Risultato della ricerca: Article

28 Citazioni (Scopus)

Abstract

Many placebo controlled trials and meta-analyses evaluatedthe efficacy of different drugs for the treatmentof inflammatory bowel disease (IBD), including immunosuppressantsand biologics. Their use is indicated inmoderate to severe disease in non responders to corticosteroidsand in steroid-dependent patients, as inductionand maintainance treatment. Infliximab, as well ascyclosporine, is considered a second line therapy in thecase of severe ulcerative colitis, or non-responders to intravenouscorticosteroids. An adequate dosage and durationof therapy with thiopurines should be reached beforeevaluating their efficacy. Methotrexate is a valid optionin patients with Crohn’s disease but its use is confined topatients who are intolerant or non-responders to thiopurines.Evidence for the use of methotrexate in ulcerativecolitis is insufficient. The use of thalidomide and mycophenolatemofetil is not recommended in patients withinflammatory bowel disease, these treatments could beconsidered in case of failure of all other therapeutic options.In patients with moderately active ulcerative colitis,refractory to thiopurines, the use of tacrolimus is consideredan alternative to biologics. An increase of the doseor a decrease in the interval of administration of biologicaltreatment could be useful in the presence of an incompleteclinical response. In the case of primary failureof an anti-tumor necrosis factor alpha a switch to anotherone should be considered. Data on the efficacy of combinationtherapy are up to now insufficient to considerthis strategy in all IBD patients. The final outcome of thetreatment should be considered the clinical remission,with mucosa healing, and not the clinical response. Theevaluation of serum concentration of thiopurine methyltransferase activity, thiopurine metabolites, biologic serumlevels and antibiologic antibodies could be useful forthe management of the treatment but it has not beenroutinely applied in clinical practice. The evidence of highrisk development of lymphoma and cutaneous malignanciesshould be considered in patients treated with immunosuppressantsand biologics for a long period.
Lingua originaleEnglish
pagine (da-a)9675-9690
Numero di pagine16
RivistaWorld Journal of Gastroenterology
Volume20
Stato di pubblicazionePublished - 2014

Fingerprint

Immunosuppressive Agents
Biological Products
Inflammatory Bowel Diseases
thiopurine methyltransferase
Ulcerative Colitis
Methotrexate
Therapeutics
Thalidomide
Tacrolimus
Crohn Disease
Meta-Analysis
Lymphoma
Mucous Membrane
Tumor Necrosis Factor-alpha
Steroids
Placebos
Skin
Antibodies
Serum
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cita questo

A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. / Cottone, Mario; Cottone, Mario; Renna, Sara; Orlando, Ambrogio; Orlando, Ambrogio; Renna, Sara.

In: World Journal of Gastroenterology, Vol. 20, 2014, pag. 9675-9690.

Risultato della ricerca: Article

Cottone, Mario ; Cottone, Mario ; Renna, Sara ; Orlando, Ambrogio ; Orlando, Ambrogio ; Renna, Sara. / A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease. In: World Journal of Gastroenterology. 2014 ; Vol. 20. pagg. 9675-9690.
@article{2fea49e759ad4f2985896bdf0ec4980e,
title = "A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.",
abstract = "Many placebo controlled trials and meta-analyses evaluatedthe efficacy of different drugs for the treatmentof inflammatory bowel disease (IBD), including immunosuppressantsand biologics. Their use is indicated inmoderate to severe disease in non responders to corticosteroidsand in steroid-dependent patients, as inductionand maintainance treatment. Infliximab, as well ascyclosporine, is considered a second line therapy in thecase of severe ulcerative colitis, or non-responders to intravenouscorticosteroids. An adequate dosage and durationof therapy with thiopurines should be reached beforeevaluating their efficacy. Methotrexate is a valid optionin patients with Crohn’s disease but its use is confined topatients who are intolerant or non-responders to thiopurines.Evidence for the use of methotrexate in ulcerativecolitis is insufficient. The use of thalidomide and mycophenolatemofetil is not recommended in patients withinflammatory bowel disease, these treatments could beconsidered in case of failure of all other therapeutic options.In patients with moderately active ulcerative colitis,refractory to thiopurines, the use of tacrolimus is consideredan alternative to biologics. An increase of the doseor a decrease in the interval of administration of biologicaltreatment could be useful in the presence of an incompleteclinical response. In the case of primary failureof an anti-tumor necrosis factor alpha a switch to anotherone should be considered. Data on the efficacy of combinationtherapy are up to now insufficient to considerthis strategy in all IBD patients. The final outcome of thetreatment should be considered the clinical remission,with mucosa healing, and not the clinical response. Theevaluation of serum concentration of thiopurine methyltransferase activity, thiopurine metabolites, biologic serumlevels and antibiologic antibodies could be useful forthe management of the treatment but it has not beenroutinely applied in clinical practice. The evidence of highrisk development of lymphoma and cutaneous malignanciesshould be considered in patients treated with immunosuppressantsand biologics for a long period.",
keywords = "biologics, immunosuppresant, inflammatory bowel disease",
author = "Mario Cottone and Mario Cottone and Sara Renna and Ambrogio Orlando and Ambrogio Orlando and Sara Renna",
year = "2014",
language = "English",
volume = "20",
pages = "9675--9690",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",

}

TY - JOUR

T1 - A. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.

AU - Cottone, Mario

AU - Cottone, Mario

AU - Renna, Sara

AU - Orlando, Ambrogio

AU - Orlando, Ambrogio

AU - Renna, Sara

PY - 2014

Y1 - 2014

N2 - Many placebo controlled trials and meta-analyses evaluatedthe efficacy of different drugs for the treatmentof inflammatory bowel disease (IBD), including immunosuppressantsand biologics. Their use is indicated inmoderate to severe disease in non responders to corticosteroidsand in steroid-dependent patients, as inductionand maintainance treatment. Infliximab, as well ascyclosporine, is considered a second line therapy in thecase of severe ulcerative colitis, or non-responders to intravenouscorticosteroids. An adequate dosage and durationof therapy with thiopurines should be reached beforeevaluating their efficacy. Methotrexate is a valid optionin patients with Crohn’s disease but its use is confined topatients who are intolerant or non-responders to thiopurines.Evidence for the use of methotrexate in ulcerativecolitis is insufficient. The use of thalidomide and mycophenolatemofetil is not recommended in patients withinflammatory bowel disease, these treatments could beconsidered in case of failure of all other therapeutic options.In patients with moderately active ulcerative colitis,refractory to thiopurines, the use of tacrolimus is consideredan alternative to biologics. An increase of the doseor a decrease in the interval of administration of biologicaltreatment could be useful in the presence of an incompleteclinical response. In the case of primary failureof an anti-tumor necrosis factor alpha a switch to anotherone should be considered. Data on the efficacy of combinationtherapy are up to now insufficient to considerthis strategy in all IBD patients. The final outcome of thetreatment should be considered the clinical remission,with mucosa healing, and not the clinical response. Theevaluation of serum concentration of thiopurine methyltransferase activity, thiopurine metabolites, biologic serumlevels and antibiologic antibodies could be useful forthe management of the treatment but it has not beenroutinely applied in clinical practice. The evidence of highrisk development of lymphoma and cutaneous malignanciesshould be considered in patients treated with immunosuppressantsand biologics for a long period.

AB - Many placebo controlled trials and meta-analyses evaluatedthe efficacy of different drugs for the treatmentof inflammatory bowel disease (IBD), including immunosuppressantsand biologics. Their use is indicated inmoderate to severe disease in non responders to corticosteroidsand in steroid-dependent patients, as inductionand maintainance treatment. Infliximab, as well ascyclosporine, is considered a second line therapy in thecase of severe ulcerative colitis, or non-responders to intravenouscorticosteroids. An adequate dosage and durationof therapy with thiopurines should be reached beforeevaluating their efficacy. Methotrexate is a valid optionin patients with Crohn’s disease but its use is confined topatients who are intolerant or non-responders to thiopurines.Evidence for the use of methotrexate in ulcerativecolitis is insufficient. The use of thalidomide and mycophenolatemofetil is not recommended in patients withinflammatory bowel disease, these treatments could beconsidered in case of failure of all other therapeutic options.In patients with moderately active ulcerative colitis,refractory to thiopurines, the use of tacrolimus is consideredan alternative to biologics. An increase of the doseor a decrease in the interval of administration of biologicaltreatment could be useful in the presence of an incompleteclinical response. In the case of primary failureof an anti-tumor necrosis factor alpha a switch to anotherone should be considered. Data on the efficacy of combinationtherapy are up to now insufficient to considerthis strategy in all IBD patients. The final outcome of thetreatment should be considered the clinical remission,with mucosa healing, and not the clinical response. Theevaluation of serum concentration of thiopurine methyltransferase activity, thiopurine metabolites, biologic serumlevels and antibiologic antibodies could be useful forthe management of the treatment but it has not beenroutinely applied in clinical practice. The evidence of highrisk development of lymphoma and cutaneous malignanciesshould be considered in patients treated with immunosuppressantsand biologics for a long period.

KW - biologics

KW - immunosuppresant

KW - inflammatory bowel disease

UR - http://hdl.handle.net/10447/127381

UR - https://www.wjgnet.com/1007-9327/full/v20/i29/9675.htm

M3 - Article

VL - 20

SP - 9675

EP - 9690

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

ER -